Objective: To determine the effects of fetal sex on aromatase and androgen receptor (AR) expression in the placenta of normal and preeclamptic pregnancies.
Introduction
The placenta is a unique and complex endocrine organ that has a crucial role during fetal development by allowing rapid exchange of nutrients and wastes between the closely apposed maternal and fetal circulatory systems. 1 In addition to the production of a wide variety of hormones and other regulatory factors, the placenta is also an endocrine target tissue, expressing a broad spectrum of hormone receptors and growth factor receptors. 2 Thus, a complex interplay of hormones and other regulatory factors produced by the placenta, mother and fetus affect placental development and functions through endocrine, paracrine and autocrine mechanisms.
Preeclampsia is a common pregnancy-specific syndrome that is characterized by hypertension and proteinuria. It is a disorder that affects at least 5% of all pregnancies worldwide. 3, 4 Preeclampsia is associated with numerous complications, including seizures, coma, low birth weight and occasionally death of the mother and/or fetus. Additionally, preeclampsia poses an increased risk for development of cardiovascular dysfunctions later in life for both child and mother. [5] [6] [7] [8] The cause of preeclampsia is unknown; however, it is generally accepted that preeclampsia results from the presence of a placenta 9 because the only effective treatment for preeclampsia is the delivery of the placenta. As such, aberrant development and functions of the placenta are implicated as important factors that contribute to preeclampsia-associated complications. Indeed, abnormalities in the placenta of women with preeclampsia have been well described; these include poor placental growth, decreased nutrient transport, improper invasion and inadequate angiogenesis and vasculogenesis. [10] [11] [12] [13] Numerous studies also demonstrate that preeclampsia alters maternal and fetal endocrine profiles including increases in the levels of testosterone and a decrease in estrogen concentrations compared with normal pregnancies. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] However, the proportion of increase in testosterone levels in preeclamptic women varies depending on the sex of fetus. Male-bearing preeclamptic women have significantly higher testosterone levels than female-bearing preeclamptic women. 21 Whether the placenta directly contributes to some of the fetal sex-related abnormal hormonal profiles in preeclampsia, or whether preeclampsia affects placental endocrine signaling pathways in relation to fetal sex, remains to be elucidated.
In this study, we evaluated whether there were any fetal sex-related differences in the expression of androgen receptor (AR) and aromatase in the placenta between healthy and preeclamptic pregnancies. Our data suggest that fetal sex-related differences in placental aromatase exist with increased levels in female and decreased levels in male preeclamptic pregnancies. The AR levels were significantly elevated in placentae with both male and female preeclamptic pregnancies. Dysregulation in androgen production, together with overexpression of their receptors in the placenta, may be associated with abnormalities of placental growth and transport, trophoblast invasion and placental angiogenesis in preeclampsia.
Methods

Placental samples
A total of 11 placentae from pregnancies with preeclampsia (5 with female and 6 with male fetuses) and 14 from normal pregnancies (7 with male and 7 with female fetuses) were collected at term (37 to 41 weeks of gestation). The patients were diagnosed with preeclampsia based on new-onset hypertension after 20 weeks of gestation such that systolic blood pressures of X140 mm Hg, diastolic blood pressures of X90 mm Hg or both were seen on two occasions X6 h apart, with significant proteinuria (X300 mg per 24 h). None of the patients had previous history of any known endocrinopathy. Excluders include smokers and alcoholics and women with chronic maternal disease (essential hypertension, connective tissue diseases, hyperthyroidism, hypothyroidism, chronic glomerulonephritis, renal failure and diabetes mellitus) or gestational diabetes. The mean gestational age in the normal pregnancies were similar to those in the preeclampsia group (Table 1 ). All samples were obtained from the Department of Obstetrics and Gynecology, University of Texas Medical Branch, from January 2009 through June 2011. The study was approved by the Institutional Review Board of the University's Human Studies Committee; informed written consent was obtained from all subjects. All patients were delivered at term. The placental tissues were collected at delivery and immediately transferred on ice to the laboratory for preparations of protein lysate, RNA isolation and tissue fixation.
Immunofluorescence
Immunofluorescence was performed on OCT-embedded frozen sections after fixing with ice-cold acetone for 10 min at room temperature. The sections were then incubated with 3% donkey serum in phosphate-buffered saline-Tween (0.01%) for 1 h at room temperature in a humidified chamber to block nonspecific antibody binding. The first primary antibody, rat anti-AR antibody (Affinity Bioreagents, Golden, CO, USA) or rabbit polyclonal anti-aromatase (Thermo Scientific, Rockford, IL, USA) was applied at 1:50 dilution overnight, followed by donkey anti-rat or anti-rabbit IgG Alexa Fluor 488 (Molecular Probes, Eugene, OR, USA). Rat or rabbit IgG (ready to use; Dako, Glostrup, Denmark) was used as a negative control. Slides were then counterstained with Hoechst 33342 (Molecular Probes). Anti-fade mounting medium (Dako) was applied and slides were viewed and captured with a constant exposure time and aperture using a single threshold value under a Nikon Eclipse E800 epifluorescence microscope (Melville, NY, USA) using a Nikon Digital camera Dxm1200. Subsequently, images were analyzed using Metamorph software (Sunnyvale, CA, USA), and the numerical output of average 488 nm pixel intensity (green fluorescence) per nuclei (blue fluorescence; Hoechst 33342) was calculated.
Western blotting
This procedure was performed with an enhanced chemiluminescence detection system. Briefly, placental villi were homogenized in ice-cold 50 mM Tris-HCl, pH 7.4, buffer containing a complete protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA). The protein concentration was measured by Bradford method (Bio-Rad, Hercules, CA, USA). Protein aliquots of 20 mg were electrophoresed in SDS-polyacrylamide gels and transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5% (w/v) non-fat dry milk, followed by incubation overnight with 1:1000 diluted antibodies against AR (Affinity Bioreagents) and aromatase (Thermo Scientific). Peroxidase-conjugated anti-rat or anti-rabbit IgG was used as the secondary antibody (Southern Biotech, Birmingham, AL, USA). All the membranes were re-blotted with 1:1000 diluted polyclonal antibody against b-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) to serve as a loading control. Specific protein bands were detected with enhanced chemiluminescence western blotting detection reagents (Affinity Bioreagents). One normal female placental sample was used on each gel to normalize density readings between gels. The specific bands were scanned and the band intensity was quantified using the Alpha ease image analysis program (Genetic Technologies, Miami, FL, USA). Results were expressed as ratios of the intensity of specific band to that of b-actin.
Quantitative reverse transcriptase PCR Total placental RNA was isolated with RNeasy kit (Qiagen, Valencia, CA, USA) according to the procedure recommended by the manufacturer. RNA extraction was followed by DNase 1 (Qiagen) treatment to remove DNA contamination. The quality and quantity of the RNA were assessed at 260/280 A, and all samples showed absorbency ratios ranging from 1.8 to 2.0. Total RNA of 1 mg was reverse transcribed into complementary DNA using avian myeloblastosis virus reverse transcriptase (Promega, Madison, WI, USA) and random oligonucleotide hexamers (Invitrogen, Carlsbad, CA, USA). For the detection of AR and ARO genes, quantitative real-time reverse transcriptase PCR was done with CFX96 system (Bio-Rad) using published primers for human AR and aromatase. The primer sequences for AR are 5 0 -CCTGGCTTCCGCAACTTACAC-3 0 (forward) and 5 0 -GGACTTGTGCATGCGGTACTCA-3 0 (reverse). The primer sequences for ARO are 5 0 -GTGGACGTGTTGACCCTTCT-3 0 (forward) and 5 0 -CACGATAGCACTTTCGTCCA-3 0 (reverse). A comparative cycle of threshold fluorescence (C T ) method was used with glyceraldehyde-3-phosphate dehydrogenase as an internal control (5 0 -GGTCTCCTCTGACTTCAACA-3 0 (forward) and 5 0 -AGCCAAATTC GTTGTCATAC-3 0 (reverse)). The C T value for glyceraldehyde-3-phosphate dehydrogenase was subtracted from the C T value for the gene of interest to give a DC T for each sample. The DC T of the calibrator (in this case the mean DC T of the placenta from normal pregnant women with female fetus) was then subtracted from each sample to give a DDC T value. This was then inserted into 2 ÀDDC T to give a final expression relative to the calibrator.
Statistical analysis
Results are expressed as mean value ± s.e.m. Comparisons between the data were performed using Graphpad prism Software (San Diego, CA, USA). Criteria for statistical significance were set at P<0.05 after two-way analysis of variance, followed by Bonferroni post hoc testing for multiple comparisons. Unpaired Student's t-test (two tailed) was used for comparisons of biological parameters between normal and preeclamptic pregnancies.
Results
Patient characteristics
In this pilot study, placentae of pregnant women bearing female (n ¼ 7) and male fetuses (n ¼ 7) served as controls for the preeclamptic placentae with female (n ¼ 5) and male fetuses (n ¼ 6). There were no significant differences in mean maternal age, mean gestational age and body mass index between the groups. The clinical and biological parameters of this agedmatched population group and sociodemographic details are shown in Table 1 . The preeclamptic patients with both male and female fetuses had a significantly higher systolic (P<0.05) and diastolic (P<0.05) blood pressure than the respective sex in normal pregnant women.
Immunofluorescence
Immunostaining of AR was barely detectable in the placentae of normal pregnancies (Figures 1a and b, top panel) . In contrast, the AR was readily detectable in the placentae of preeclamptic pregnancies and was significantly greater in the placentae with both female (P ¼ 0.002) and male (P ¼ 0.019) fetuses compared with their respective sexes in normal pregnancies (Figures 1a and  b, bottom panel) . The AR staining intensity did not significantly vary between fetal sex when compared within the normal and preeclamptic placentae (Figures 1e, top panel) . Immunostaining of AR in the preeclamptic placentae was mainly found in the syncytiotrophoblasts (Figures 1a and b, bottom panel) .
The immunostaining intensity of aromatase in the preeclamptic placentae varied depending on fetal sex. If the fetus was a female, the staining intensity for aromatase was substantially higher (P ¼ 0.04) in the preeclamptic placentae than in the normal placentae (Figures 1c and e, lower panel) . On the other hand, if the fetus was a male, the staining intensity for aromatase was significantly lower (P ¼ 0.01) in the preeclamptic placentae than in the normal placentae (Figure 1d and e, lower panel) . Within the placentae of normal pregnancies, aromatase-staining intensity was significantly higher (P ¼ 0.03) in placentae with male than with female fetus (Figure 1e, bottom panel) . On the other hand, the aromatase-staining intensity was significantly lower (P ¼ 0.01) in male than female preeclamptic placentae (Figure 1e ). Aromatase protein was exclusively localized in the syncytiotrophoblast in the control and preeclamptic placentae (Figures 1c and d) . No detectable staining was observed when primary antibody to AR or aromatase was omitted (procedure control; data not shown).
Western blot
To further verify the changes in AR in the preeclamptic placentae, western blotting analyses were performed. Consistent with the immunohistochemical observations, the levels of AR protein (110 kDa) are significantly elevated (P ¼ 0.001) in the placentae of preeclamptic women compared with normal pregnant women, Fetal sex and placental androgenic networks K Sathishkumar et al and fetal sex had no effect (Figure 2a ). Within the normal and preeclamptic pregnancies, there were no significant differences between sexes on levels of AR protein (Figure 2a ). The levels of aromatase protein (55 kDa) were markedly increased in preeclamptic placentae with female fetuses (P ¼ 0.004), whereas the levels were significantly decreased in placentae with male fetuses (P ¼ 0.01) compared with the respective sexes in normal placentae (Figure 2b) . The normal placentae with male fetuses have significantly higher (P ¼ 0.04) levels of aromatase protein than the normal placentae with female fetuses. Conversely, preeclamptic placentae with male fetuses have significantly lower (P ¼ 0.001) levels of aromatase protein than female preeclamptic placentae (Figure 2b ).
Quantitative reverse transcriptase PCR
To examine whether preeclampsia also altered the expression of AR and ARO (also known as CYP19) genes, quantitative reverse transcriptase PCR analyses were carried out. The results showed that the levels of AR mRNA were significantly elevated in the placentae with male (P ¼ 0.03) and female (P ¼ 0.001) fetuses in preeclamptic women compared with their respective sexes in the placentae from normal women (Figure 3a) . The increase in levels of AR mRNA in the male preeclamptic compared with the female preeclamptic placentae was not statistically significant (P ¼ 0.33; Figure 3a) .
The levels of aromatase mRNA in preeclamptic placentae were significantly higher if the fetus was a female (P ¼ 0.04), whereas the levels were significantly lower if the fetus was a male (P ¼ 0.04) compared with their respective sexes in normal placentae (Figure 3b ). The levels of aromatase mRNA in the normal placentae were significantly higher in male than in female fetus (P ¼ 0.02; Figure 3b ). On the other hand, in the preeclamptic placentae the aromatase mRNA levels were significantly lower in male than in female fetus (P<0.04; Figure 3b ). Changes in AR and aromatase protein levels are consistent with changes in their mRNA abundance, suggesting that preeclampsia may influence placental gene expression of the AR and aromatase at the transcriptional level.
Discussion
The placenta is an endocrine organ that has an important role during pregnancy. The placenta produces numerous hormones that regulate maternal function and fetal growth. There have been a number of reports that women with preeclampsia have higher plasma testosterone levels compared with those of healthy pregnant women. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Although the origin of the increased androgens during pregnancy remains uncertain, studies suggest that the elevation of testosterone production during pregnancy is likely of ovarian origin. 26, 27 Whether the placenta also contributes to the increased testosterone levels in the maternal circulation remains largely unresolved. 26, 28, 29 Although the human placenta lacks 17b-hydroxylase and 17,20-desmolase, 30 it does express 17b-hydroxysteroid dehydrogenase 31 and aromatase, as well as 3b-hydroxysteroid dehydrogenase. 32 The placenta can therefore synthesize androstenedione from adrenal or ovarian dehydroepiandrosterone sulphate and can undertake the onward synthesis of both testosterone and estradiol. Normally, androgens synthesized by the placenta are rapidly converted to estrogens by the placental aromatase, 33, 34 and therefore the placental androgens may contribute only slightly to the increased androgen observed in normal pregnancy. In this study, the placental mRNA and protein levels of aromatase, a rate-limiting enzyme converting androgens to estrogens, varied depending on fetal sex. If the fetus was a female, the aromatase expression was higher in the preeclamptic than in the normal placentae. On the other hand if the fetus was a male, the aromatase expression was lower in the preeclamptic than in the normal placentae. Previous studies suggest that maternal testosterone levels are higher in preeclamptic pregnancies irrespective of the sex of the fetus compared with normal pregnancies. However, testosterone levels are significantly higher in male-than in female-bearing preeclamptic pregnancies. 35 On the basis of our findings, it is possible that the increased expression of aromatase in the placentae of female fetus-bearing preeclamptic women could have partially metabolized the excess testosterone contributing for relatively lower maternal testosterone levels. This may be an adaptive protective mechanism to prevent the female fetuses from virilization when the mothers themselves have high circulating testosterone levels. Despite higher aromatase levels in the preeclamptic placentae of female fetus, higher maternal circulating levels are observed in female-bearing preeclamptic pregnancies, 36 suggesting that testosterone production is higher such that the increased expression of aromatase may not be sufficient to metabolize androgens to levels that are observed in normal pregnancies. In the placenta with male fetus, the decrease in aromatase levels could have contributed for the relatively higher testosterone levels by altering the equilibrium between estrogens and androgens in favor of androgens. These findings imply that increased testosterone during preeclamptic pregnancies may be primarily of non-placental origin but the placenta, depending on fetal sex, may modulate the levels of maternal testosterone. Thus, the fetal sex-specific abnormal maternal profile of androgens in preeclampsia may be attributed, at least in part, to altered aromatase levels in the placenta. It would be interesting to assess whether such fetal sex-dependent differential expression in aromatase levels also exists in tissues or organs other than the placenta.
The mechanisms that contribute to the inhibition of aromatase in the preeclamptic placenta with male fetus are not known. In the placenta, the major factors involved in regulating aromatase activity (retinoids, 37 tumor necrosis factor-a 38 and lipid radicals 39 ) are all dysregulated during preeclampsia in a way that could potentially downregulate aromatase. [40] [41] [42] [43] Aromatase expression in the trophoblast is barely detectable under hypoxic conditions 44 (which mirror the actual conditions of the placenta in the context of preeclampsia). Moreover, insulin 15 and leptin, 30 which are significantly increased in preeclamptic patients, have been shown to inhibit aromatase in human cytotrophoblasts. Why the inhibitory effect of the placental aromatase is specific to male sex is not known at this time. It is suggested that the placenta with female fetus has greater adaptability to adverse maternal environment than the placenta with male fetus. 45 Similar findings of fetal sex-specific differences in the placental cytokine expression, the insulin-like growth factor pathways and the placental response to cortisol in relation to the complication of asthma during pregnancy are reported. [46] [47] [48] [49] Even in the normal pregnancies, the placentae with male fetus have higher aromatase levels than the placentae with female fetus. The male fetus produces testosterone starting as early as 8 weeks of age, with peak levels reaching up to 150 ng dl À1 around mid-to late-gestation. Despite greater production of testosterone by male fetus, the maternal testosterone levels are not significantly different between the male-and female-bearing normal pregnant women. 35 This suggests that the increased aromatase levels in placentae of male fetus may act as an effective barrier to prevent transfer of testosterone from fetal side to maternal circulation.
Previous studies show inconclusive results regarding the presence of AR in the human placenta. [50] [51] [52] [53] In this study, we show that the mRNA and protein of AR are detectable in the syncytiotrophoblasts. The most significant finding of this study is that the expression of AR in the preeclampsia placentae is considerably increased irrespective of fetal sex compared with their respective sexes in normal pregnancies. Although there is no information available at this time regarding the role of androgen signaling in the placenta, androgens are known to be pleiotropic hormones with genomic and non-genomic activity involving a myriad of biological processes. Dysregulation in androgen signaling in the placenta may profoundly interfere with its development and function. It is well known that increase in testosterone levels and altered in utero environment during pregnancy increase the risk of cardiovascular dysfunction in the mothers, [5] [6] [7] [8] as well as program for adult life cardiovascular, metabolic and endocrine dysfunctions in the offspring. [54] [55] [56] [57] [58] Therefore, it is likely that a combination of overexpression of the placental AR and fetal sex-specific dysregulation in the placental androgen production in preeclampsia may have a significant role in contributing for development of gender-specific diseases later in life.
Although this pilot study provided initial evidence for the increased placental AR levels in preeclamptic pregnancies and the placental aromatase levels varied in a fetal sex-specific manner in both normal and preeclamptic pregnancies, the limited number of patients is a potential weakness. Our results will have to be confirmed in a larger cohort, with longitudinal data to assess the full impact of our studies.
Conclusion
The aromatase levels in placentae vary depending on fetal sex in normal and preeclamptic pregnancies. In preeclamptic pregnancies with male fetuses, the observed increase in circulating testosterone may be partly associated with the decrease in the placental aromatase that reduces the conversion of testosterone to estrogens. In preeclamptic pregnancies with female fetuses, the relatively lower circulating testosterone may be due to the increased placental aromatase levels. The placental AR levels are upregulated in preeclamptic pregnancies with both fetal sexes, suggesting that the androgen-signaling pathways may be overactivated in the placentae of pregnancies with preeclampsia. Dysregulation of these androgen-signaling networks may be involved in the development of placental abnormalities, which eventually increase the frequency of maternal and fetal complications associated with preeclampsia.
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